Evernorth Reports $233.7 Million Impairment on XRP Reserves, Plans to Enhance Returns through DeFi Strategies
According to Golden Finance, XRP treasury company Evernorth Holdings disclosed in its SPAC listing-related S-4 filing that its digital assets experienced an impairment of approximately $233.7 million in 2025, primarily due to the difference between the purchase cost and the market price during the reporting period. The document shows that by the end of 2025, Evernorth and Pathfinder Digital Assets held approximately 473.1 million XRP, of which the company purchased 84.4 million XRP for about $214.1 million, with an average cost of approximately $2.54 per coin, while the current XRP price is about $1.45, a decrease of about 35% from the cost. Evernorth stated that it will actively manage its XRP reserves rather than hold them passively, planning to introduce the RLUSD stablecoin to participate in decentralized finance transactions within the XRP ecosystem, including the construction of RLUSD/XRP liquidity pools, while enhancing asset returns through lending XRP, providing AMM liquidity, and options strategies such as covered calls and cash-secured puts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
